Krina K. Patel, MD, MSc

Krina K. Patel, MD, MSc, is an associate professor in the Department of Lymphoma/Myeloma in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center.

Articles

Dr Patel on the Efficacy of Anitocabtagene Autoleucel in R/R Multiple Myeloma

December 8th 2025

Krina K. Patel, MD, MSc, discusses the efficacy of anitocabtagene autoleucel in relapsed/refractory multiple myeloma from the iMMagine-1 trial.

Earlier CAR T Use in Multiple Myeloma: Game Changer or Boutique Medicine?

May 7th 2024

Krina K. Patel, MD, MSc, discusses her thoughts on moving CAR T-cell therapy up in the lines of treatment for patients with multiple myeloma.

Dr Patel on the FDA Approval of Ide-Cel for Triple Class–Exposed R/R Multiple Myeloma

April 5th 2024

Krina K. Patel, MD, MSc, discusses the FDA approval of ide-cel for patients with triple class–exposed relapsed/refractory multiple myeloma.

Treatment Considerations and Sequencing in Multiple Myeloma

February 19th 2024

The expert panel concludes their discussion with clinical insights on treatment sequencing and therapeutic decision-making for patients who have relapsed.

CAR T-Cell Therapy in Multiple Myeloma: Role in the Treatment Landscape

February 19th 2024

A roundtable discussion on the evolving treatment landscape surrounding CAR T-cell therapy in multiple myeloma, with a focus on future directions and the management of adverse events.

GPRC5D-Targeting Bispecifics in Multiple Myeloma

February 12th 2024

The expert panel discusses recent clinical trial data on GPRC5D-targeting bispecific antibodies and how they apply to the multiple myeloma treatment paradigms.

Adverse Effects Related to Bispecifics in Multiple Myeloma

February 12th 2024

Comprehensive insights on the adverse effects seen from bispecific antibodies in the treatment of patients with multiple myeloma.

Step-Up Dosing Practices for Bispecifics in Multiple Myeloma

February 5th 2024

Multiple myeloma specialists compare step-up dosing practices and provide clinical insights on treating patients with multiple myeloma.

Real-World Evidence and Selecting Optimal Bispecifics in Multiple Myeloma

February 5th 2024

Experts on multiple myeloma discuss how real-world evidence informs treatment selection for patients receiving bispecific antibodies.

Updates on BCMA-Targeting Bispecifics in MM

January 29th 2024

An expert panel reviews recent updates on BCMA-targeting bispecific antibodies in multiple myeloma.

Potential Role for CAR T-Cell Therapy in MM at Early Relapse

January 29th 2024

Krina Patel, MD, reviews data from the CARTITUDE-4 and KarMMa-3 studies and shares perspectives on a potential role for CAR T-cell therapy at early relapse.

Treatment of Multiple Myeloma at Early Relapse

January 22nd 2024

A panel of expert hematologic-oncologists offer insights on how they treat patients with multiple myeloma at early relapse.

The Evolving Treatment Paradigm for Transplant Ineligible MM

January 22nd 2024

The expert panel discusses how the standard of care for transplant-ineligible NDMM has evolved and reviews recent updates in this space.

Role of Transplant and MRD in Newly Diagnosed MM

January 15th 2024

Amrita Krishnan, MD, and Saad Z. Usmani, MD, MBA, FACP, offer their perspectives on the role of stem cell transplant and MRD testing in patients with newly diagnosed multiple myeloma.

Advances in the Treatment of High-Risk MM

January 15th 2024

Clinical insights on the definition of high-risk multiple myeloma and the treatment of patients with high risk disease, including how the results from the IsKia trial might impact practice.

Highlights from ASH 2023 in Transplant-Eligible NDMM

January 15th 2024

Experts in multiple myeloma discuss highlights from the ASH 2023 meeting around transplant-eligible NDMM with particular focus on the PERSEUS and GRIFFIN trials and the clinical implications of the results of these studies.

The Evolving Landscape of Newly Diagnosed Multiple Myeloma

December 14th 2023

A panel of experts discuss the evolving landscape of newly diagnosed multiple myeloma.

Dr Patel on Maintaining Quality of Life While Treating Patients With Multiple Myeloma

August 15th 2023

Krina K. Patel, MD, MSc, discusses maintaining quality of life while treating patients with multiple myeloma, as well as highlights from the phase 3 KarMMa-3 trial.

Dr Patel on the Background of the KarMMa-3 Trial in Relapsed/Refractory Multiple Myeloma

August 8th 2023

Krina K. Patel, MD, MSc, discusses the background of the phase 3 KarMMa-3 trial, which investigated idecabtagene vicleucel in patients with high-risk, relapsed/refractory multiple myeloma.

Dr Patel on Safety Data and Biomarker Outcomes With Ide-Cel in High-Risk R/R Multiple Myeloma

July 21st 2023

Krina K. Patel, MD, MSc, discusses the safety profile of idecabtagene vicleucel in a subgroup of patients with high-risk, relapsed/refractory multiple myeloma, as well as findings with soluble BCMA levels from the phase 3 KarMMa-3 trial.